Phase 1 Safety and Pharmacokinetic Study of AI-700 in Patients With Diminished DLCO and COPD and/or CHF
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
0
Participant gender:
Summary
This study was conducted to evaluate the safety and pharmacokinetics of an echocardiographic
contrast agent, AI-700, in patients with moderate to severe chronic obstructive pulmonary
disease (COPD) and/or congestive heart failure (CHF).